The January 1 change is no longer a future deadline. If you use a GLP-1 medication and have Medi-Cal Rx, the useful question now is not simply “is this drug covered?” It is “what condition is documented for this prescription, what coverage pathway applies to that use, and what information does Medi-Cal Rx need before the next fill?”
Quick Answer
As of January 1, 2026, Medi-Cal Rx no longer covers the listed GLP-1 drugs when they are used for weight loss only. Previously approved prior authorizations for weight-loss use ended December 31, 2025. Coverage may still be available for certain non-weight-loss uses. Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity may continue to be covered for type 2 diabetes when the required diagnosis information is submitted. Wegovy has separate coverage pathways for specified non-weight-loss conditions, and Zepbound has a separate pathway for obstructive sleep apnea. Medi-Cal members younger than 21 may have a limited weight-loss coverage pathway when a prior authorization is submitted and approved under the EPSDT benefit. A benefit change is not a treatment instruction: do not stop, restart, substitute, or change the dose of a medication solely because a claim is denied.
What Changed on January 1, 2026
Medi-Cal Rx implemented a statewide policy change tied to California’s 2025–26 State Budget. The listed GLP-1 drugs are no longer covered when they are used for weight loss only.
- Wegovy
- Weight-loss-only coverage ended. Separate coverage pathways remain for specified non-weight-loss conditions.
- Saxenda
- Weight-loss-only coverage ended, and previously approved weight-loss prior authorizations ended December 31.
- Zepbound
- Weight-loss-only coverage ended. A separate prior-authorization pathway may apply for obstructive sleep apnea.
- Other listed GLP-1 drugs
- Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity are no longer covered for weight loss only.
Coverage Change Does Not Mean “All GLP-1 Coverage Ended”
The January policy is indication-specific. Some listed medications may still qualify for Medi-Cal Rx coverage when they are prescribed for a documented non-weight-loss condition and the required coverage information is submitted.
Start by Reviewing the Current Prescription, Not the Drug Name Alone
Two Medi-Cal members can use the same medication and have different coverage results because the documented reason for use can be different. Before the next refill, identify what is actually on the current prescription and what condition the prescriber is treating.
Which description fits the current prescription?
Weight loss only
Medi-Cal Rx no longer covers the listed GLP-1 drugs for weight-loss-only use as of January 1, 2026. Previously approved weight-loss prior authorizations ended December 31, 2025.
Type 2 diabetes
Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity may continue to be covered when the required diagnosis information is submitted with the prescription.
Other documented condition
Certain non-weight-loss uses have separate coverage pathways. Ask the pharmacy or prescriber whether the documented condition needs a diagnosis code, prior authorization, or another Medi-Cal Rx review step.
Member younger than 21
A Medi-Cal member younger than 21 who needs a GLP-1 drug for weight loss may have a coverage pathway when a prior-authorization request is submitted and approved under the EPSDT benefit requirements.
Do Not Guess the Diagnosis From the Medication
Ask the prescriber or review your current records if you are unsure why the medication is being prescribed. The pharmacy can help explain what information appears on the prescription and what the claim response shows.
Coverage Paths Differ by the Documented Use
The January policy separates weight-loss-only use from certain other conditions. That is why the same medication name can produce a different claim or authorization requirement depending on the prescription.
- Type 2 diabetes
- Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity may continue to be covered when the required diagnosis information is submitted.
- Wegovy for cardiovascular disease
- A prior-authorization request may be reviewed for this documented non-weight-loss use.
- Wegovy for MASH
- Medi-Cal Rx identifies a coverage pathway when the required diagnosis information is submitted with the prescription.
- Zepbound for obstructive sleep apnea
- A prior-authorization request may be reviewed for this documented non-weight-loss use.
Other non-weight-loss uses may require additional review. Patients should not assume coverage from the medication name alone or submit their own medical-necessity argument. The prescriber and pharmacy provider handle the clinical and claim information required for the coverage process.
Check Whether the Next Step Is a Diagnosis Code or Prior Authorization
Medi-Cal Rx uses different coverage mechanisms for different GLP-1 uses. For some type 2 diabetes prescriptions, the prescriber may need to submit the diagnosis code with the prescription. Other documented uses may require a prior-authorization request.
A prior authorization is a coverage request submitted by the pharmacy provider or prescriber. It is not a guarantee of approval, and patients should not delay contacting the prescriber when the next refill is approaching.
01. What condition is documented for my current GLP-1 prescription?
01. Most statutory changes in the Board’s 2026 law summary took effect January 1, 2026 unless otherwise noted.
02. Did my prior authorization end on December 31, 2025?
03. Does the prescription need a diagnosis code for the claim to process?
04. Does my current use require a new prior-authorization request?
05. Has the pharmacy received a denial code or Notice of Action information?
06. Who is handling the next step: the pharmacy, prescriber, Medi-Cal Rx, or more than one of them?
A Denied Claim Is Not Permission to Change Treatment
Do not skip doses, double later doses, use someone else’s medication, or change the prescribed regimen because coverage changed. Contact the prescriber for treatment decisions and the pharmacy or Medi-Cal Rx for benefit questions.
If Coverage Is Denied, Read the Notice Before Deciding What to Do
Medi-Cal members who receive a Notice of Action denying GLP-1 coverage have the right to request a State Hearing. Medi-Cal Rx states that members generally have 90 days from the date of the Notice of Action to request the hearing.
For a member who was taking a GLP-1 drug on or before January 1, 2026, a shorter timing rule can matter when the member wants to request continued coverage while the hearing is pending. Medi-Cal Rx advises that a hearing request generally needs to be submitted within 10 days of receiving the denial notice and identify that continued medication coverage is being requested. The actual notice and hearing instructions should be followed because continuation is subject to specific conditions and can end before the hearing process is complete.
- Read the Notice of Action
- Use the denial notice to identify the reason, hearing rights, and applicable deadlines.
- 90-day general hearing window
- Medi-Cal Rx states that members generally have 90 days from the notice date to request a State Hearing.
- 10-day timing may matter
- A shorter window can apply when requesting continued coverage while a hearing is pending.
- Medi-Cal Rx help
- The Customer Service Center is available at 1-800-977-2273 for benefit and prior-authorization questions.
Review the Prescription and the Claim Path Together
Fireside Pharmacy can help explain prescription details, refill status, pharmacy claim messages, transfer, pickup, and delivery while the prescriber handles clinical decisions.
A January GLP-1 Coverage Review Checklist
Use this list before the next refill so you know which part of the process still needs attention.
01. Confirm the exact GLP-1 medication, strength, dosage form, and current directions.
02. Ask whether a prior authorization that applied before January 1 ended on December 31.
03. If coverage is denied, keep the Notice of Action and review the hearing instructions and deadlines promptly.
04. Confirm the documented condition for which the medication is currently prescribed.
05. Ask whether the next claim needs a diagnosis code, new prior authorization, or another coverage step.
06. Use Medi-Cal Rx Customer Service at 1-800-977-2273 for benefit or prior-authorization status questions.
Frequently Asked Questions
Did Medi-Cal Rx stop covering every GLP-1 drug on January 1, 2026?
No. Medi-Cal Rx stopped covering the listed GLP-1 drugs for weight-loss-only use. Certain non-weight-loss uses may still qualify for coverage when the required diagnosis or prior-authorization information is submitted.
What happened to an approved GLP-1 prior authorization for weight loss?
Previously approved prior authorizations for weight-loss use ended December 31, 2025. They did not continue into 2026 simply because they had an approval date extending beyond the end of 2025.
Can Medi-Cal Rx still cover a GLP-1 medication for type 2 diabetes?
For Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity, Medi-Cal Rx states that coverage for type 2 diabetes can continue when the required diagnosis information is submitted with the prescription.
Is there an exception for Medi-Cal members younger than 21?
Yes. A member younger than 21 who needs a GLP-1 drug for weight loss may have a coverage pathway if the pharmacy provider or prescriber submits a prior-authorization request and it is approved under the EPSDT benefit requirements.
What should I do if Medi-Cal Rx denies coverage?
Read the Notice of Action, contact the pharmacy or Medi-Cal Rx for the benefit reason, and contact the prescriber for treatment decisions. The notice includes State Hearing rights and deadlines that can be important if you want to challenge the denial.
Review the Coverage Path Before the Next Fill
Use the form above to request a call about prescription details, refill status, pharmacy claim messages, transfer, pickup, or delivery.
